NCT02251691 is a Phase 4 clinical trial of Advagraf in Adherence to Medication Regime, sponsored by National Taiwan University Hospital.

Who is sponsoring NCT02251691?

NCT02251691 is sponsored by National Taiwan University Hospital.

What drugs are being tested in NCT02251691?

Interventions in NCT02251691: Advagraf, Prograf.

What condition does NCT02251691 study?

NCT02251691 studies Adherence to Medication Regime.

Is NCT02251691 still recruiting?

NCT02251691 is currently status unknown. Last updated 2 April 2019.

Last reviewed 2019-04-02 · How we verify

NCT02251691

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Influence of Once-daily Versus Twice-daily Immunosuppressant on Renal Transplant

Status unknown Phase 4 Last updated 2 April 2019

What this trial tests

Phase 4 trial testing Advagraf in Adherence to Medication Regime in 90 participants. Status unknown.

Timeline

9 May 2014

Primary endpoint
31 March 2020

31 March 2020

Quick facts

Lead sponsor	National Taiwan University Hospital
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	90
Start date	9 May 2014
Primary completion	31 March 2020
Estimated completion	31 March 2020
Sites	1 location across Taiwan

Drugs / interventions tested

Advagraf — full drug profile →
Prograf — full drug profile →

Conditions studied

Adherence to Medication Regime — all drugs for Adherence to Medication Regime →

Sponsor

National Taiwan University Hospital

Who can join

Adults 20 to 65, any sex, with Adherence to Medication Regime. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of this study was to compare the drug compliance in patients after renal transplantation under once or twice-daily tacrolimus-based immunosuppressive regimen. The rationale for this study is to access the influence of once-daily prolonged-release tacrolimus versus standard twice-daily tacrolimus on drug compliance in renal transplantation recipients base on the assumption that once-daily dosing regimen may help to improve drug compliance.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Interventions for increasing immunosuppressant medication adherence in solid organ transplant recipients.
Mellon L, Doyle F, Hickey A, Ward KD, et al · · 2022 · cited 20× · PMID 36094829 · DOI 10.1002/14651858.cd012854.pub2

Verify or expand the search:

Other trials of Advagraf

Trials testing the same drug.

NCT03603548 — Comparison of Safety and Efficacy of Two Variants of Prolonged - Released Tacrolimus (Advagraf vs. Envarsus ) in Patient · NA · unknown
NCT03216447 — A Study of Patient Adherence and Convenience to Immunosuppressive Agents in Newly Liver Transplant · Phase 4 · unknown
NCT02034747 — A Study to Assess the Efficacy and Safety of Advagraf® Switching From Cyclosporine Between the Group That Was Treated Wi · Phase 4 · completed
NCT02268201 — A Study to Evaluate the Efficacy and Safety in Kidney Transplant Recipients When Changed From Cyclosporine to Tacrolimus · Phase 4 · terminated
NCT01882322 — A Study to Evaluate the Effect of Advagraf Conversion From Prograf in Liver Transplant Subjects · Phase 4 · completed

Other National Taiwan University Hospital trials

Trials by the same sponsor.

NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02251691 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
Last refreshed: 2 April 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02251691.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing